Loading…
Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines
Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorino...
Saved in:
Published in: | Journal of medicinal chemistry 2016-09, Vol.59 (18), p.8233-8262 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623 |
---|---|
cites | cdi_FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623 |
container_end_page | 8262 |
container_issue | 18 |
container_start_page | 8233 |
container_title | Journal of medicinal chemistry |
container_volume | 59 |
creator | Yang, Eugene Guorong Mustafa, Nurulhuda Tan, Eng Chong Poulsen, Anders Ramanujulu, Pondy Murugappan Chng, Wee Joo Yen, Jeffrey J. Y Dymock, Brian W |
description | Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is 50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule. |
doi_str_mv | 10.1021/acs.jmedchem.6b00157 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1823031069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1823031069</sourcerecordid><originalsourceid>FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623</originalsourceid><addsrcrecordid>eNp9kd1u1DAQhS0EokvhDRDy5fYii3-T9HK7W7ptVwIJuI4cZ9KdKrGX2AHtq_F0eP96yc1Y1nznjD2HkI-czTgT_LOxYfbcQ2M30M_ymjGui1dkwrVgmSqZek0mjAmRiVzIC_IuhGfGmORCviUXotCKS11MyN8lBHxy1LiGft-5uEnXQH1LH4wbA31EZwJQQacP80dxdcBWGKJ3QJdgLMRutwemq-V8cUVvMGzBYouW3rsN1hj9EOhNIhrqHf1m7IARHdYHo9vf2ICzsB-3HE2X-nHzx-zOWkwSdHQFvYm-809oE7OArqNrdBDekzet6QJ8OJ2X5OeX2x-LVbb-ene_mK8zI1UZM85yZYTkDeOgSi1V0bZ5LkwLOpVag2SWq-tUC95oqUstOIAqjJTC8LS8SzI9-m4H_2uEEKseg03PMA78GCpeCpkWy_LrhKojagcfwgBttR2wN8Ou4qzap1al1KpzatUptST7dJow1qn3IjrHlAB2BA5yPw4uffj_nv8AAjel_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1823031069</pqid></control><display><type>article</type><title>Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)</source><creator>Yang, Eugene Guorong ; Mustafa, Nurulhuda ; Tan, Eng Chong ; Poulsen, Anders ; Ramanujulu, Pondy Murugappan ; Chng, Wee Joo ; Yen, Jeffrey J. Y ; Dymock, Brian W</creator><creatorcontrib>Yang, Eugene Guorong ; Mustafa, Nurulhuda ; Tan, Eng Chong ; Poulsen, Anders ; Ramanujulu, Pondy Murugappan ; Chng, Wee Joo ; Yen, Jeffrey J. Y ; Dymock, Brian W</creatorcontrib><description>Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, submicromolar potent against HDACs 1, 8, and 11, and >50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.6b00157</identifier><identifier>PMID: 27541357</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Apoptosis - drug effects ; Bridged-Ring Compounds - chemistry ; Bridged-Ring Compounds - pharmacology ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Hematologic Neoplasms - drug therapy ; Hematologic Neoplasms - metabolism ; Histone Deacetylase Inhibitors - chemistry ; Histone Deacetylase Inhibitors - pharmacology ; Humans ; Janus Kinase 2 - antagonists & inhibitors ; Models, Molecular ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - pharmacology ; Pyrimidines - chemistry ; Pyrimidines - pharmacology ; Signal Transduction - drug effects</subject><ispartof>Journal of medicinal chemistry, 2016-09, Vol.59 (18), p.8233-8262</ispartof><rights>Copyright © 2016 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623</citedby><cites>FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27541357$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Eugene Guorong</creatorcontrib><creatorcontrib>Mustafa, Nurulhuda</creatorcontrib><creatorcontrib>Tan, Eng Chong</creatorcontrib><creatorcontrib>Poulsen, Anders</creatorcontrib><creatorcontrib>Ramanujulu, Pondy Murugappan</creatorcontrib><creatorcontrib>Chng, Wee Joo</creatorcontrib><creatorcontrib>Yen, Jeffrey J. Y</creatorcontrib><creatorcontrib>Dymock, Brian W</creatorcontrib><title>Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, submicromolar potent against HDACs 1, 8, and 11, and >50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule.</description><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Bridged-Ring Compounds - chemistry</subject><subject>Bridged-Ring Compounds - pharmacology</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Hematologic Neoplasms - drug therapy</subject><subject>Hematologic Neoplasms - metabolism</subject><subject>Histone Deacetylase Inhibitors - chemistry</subject><subject>Histone Deacetylase Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Janus Kinase 2 - antagonists & inhibitors</subject><subject>Models, Molecular</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Pyrimidines - chemistry</subject><subject>Pyrimidines - pharmacology</subject><subject>Signal Transduction - drug effects</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9kd1u1DAQhS0EokvhDRDy5fYii3-T9HK7W7ptVwIJuI4cZ9KdKrGX2AHtq_F0eP96yc1Y1nznjD2HkI-czTgT_LOxYfbcQ2M30M_ymjGui1dkwrVgmSqZek0mjAmRiVzIC_IuhGfGmORCviUXotCKS11MyN8lBHxy1LiGft-5uEnXQH1LH4wbA31EZwJQQacP80dxdcBWGKJ3QJdgLMRutwemq-V8cUVvMGzBYouW3rsN1hj9EOhNIhrqHf1m7IARHdYHo9vf2ICzsB-3HE2X-nHzx-zOWkwSdHQFvYm-809oE7OArqNrdBDekzet6QJ8OJ2X5OeX2x-LVbb-ene_mK8zI1UZM85yZYTkDeOgSi1V0bZ5LkwLOpVag2SWq-tUC95oqUstOIAqjJTC8LS8SzI9-m4H_2uEEKseg03PMA78GCpeCpkWy_LrhKojagcfwgBttR2wN8Ou4qzap1al1KpzatUptST7dJow1qn3IjrHlAB2BA5yPw4uffj_nv8AAjel_g</recordid><startdate>20160922</startdate><enddate>20160922</enddate><creator>Yang, Eugene Guorong</creator><creator>Mustafa, Nurulhuda</creator><creator>Tan, Eng Chong</creator><creator>Poulsen, Anders</creator><creator>Ramanujulu, Pondy Murugappan</creator><creator>Chng, Wee Joo</creator><creator>Yen, Jeffrey J. Y</creator><creator>Dymock, Brian W</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160922</creationdate><title>Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</title><author>Yang, Eugene Guorong ; Mustafa, Nurulhuda ; Tan, Eng Chong ; Poulsen, Anders ; Ramanujulu, Pondy Murugappan ; Chng, Wee Joo ; Yen, Jeffrey J. Y ; Dymock, Brian W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Bridged-Ring Compounds - chemistry</topic><topic>Bridged-Ring Compounds - pharmacology</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Hematologic Neoplasms - drug therapy</topic><topic>Hematologic Neoplasms - metabolism</topic><topic>Histone Deacetylase Inhibitors - chemistry</topic><topic>Histone Deacetylase Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Janus Kinase 2 - antagonists & inhibitors</topic><topic>Models, Molecular</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Pyrimidines - chemistry</topic><topic>Pyrimidines - pharmacology</topic><topic>Signal Transduction - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Eugene Guorong</creatorcontrib><creatorcontrib>Mustafa, Nurulhuda</creatorcontrib><creatorcontrib>Tan, Eng Chong</creatorcontrib><creatorcontrib>Poulsen, Anders</creatorcontrib><creatorcontrib>Ramanujulu, Pondy Murugappan</creatorcontrib><creatorcontrib>Chng, Wee Joo</creatorcontrib><creatorcontrib>Yen, Jeffrey J. Y</creatorcontrib><creatorcontrib>Dymock, Brian W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Eugene Guorong</au><au>Mustafa, Nurulhuda</au><au>Tan, Eng Chong</au><au>Poulsen, Anders</au><au>Ramanujulu, Pondy Murugappan</au><au>Chng, Wee Joo</au><au>Yen, Jeffrey J. Y</au><au>Dymock, Brian W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2016-09-22</date><risdate>2016</risdate><volume>59</volume><issue>18</issue><spage>8233</spage><epage>8262</epage><pages>8233-8262</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, submicromolar potent against HDACs 1, 8, and 11, and >50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>27541357</pmid><doi>10.1021/acs.jmedchem.6b00157</doi><tpages>30</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 2016-09, Vol.59 (18), p.8233-8262 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_1823031069 |
source | American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list) |
subjects | Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Apoptosis - drug effects Bridged-Ring Compounds - chemistry Bridged-Ring Compounds - pharmacology Cell Line, Tumor Cell Proliferation - drug effects Hematologic Neoplasms - drug therapy Hematologic Neoplasms - metabolism Histone Deacetylase Inhibitors - chemistry Histone Deacetylase Inhibitors - pharmacology Humans Janus Kinase 2 - antagonists & inhibitors Models, Molecular Protein Kinase Inhibitors - chemistry Protein Kinase Inhibitors - pharmacology Pyrimidines - chemistry Pyrimidines - pharmacology Signal Transduction - drug effects |
title | Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T06%3A22%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design%20and%20Synthesis%20of%20Janus%20Kinase%202%20(JAK2)%20and%20Histone%20Deacetlyase%20(HDAC)%20Bispecific%20Inhibitors%20Based%20on%20Pacritinib%20and%20Evidence%20of%20Dual%20Pathway%20Inhibition%20in%20Hematological%20Cell%20Lines&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Yang,%20Eugene%20Guorong&rft.date=2016-09-22&rft.volume=59&rft.issue=18&rft.spage=8233&rft.epage=8262&rft.pages=8233-8262&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.6b00157&rft_dat=%3Cproquest_cross%3E1823031069%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1823031069&rft_id=info:pmid/27541357&rfr_iscdi=true |